BENEFICIAL PROPERTIES OF NIGELLA SATIVA (BLACK CUMIN)
DOI:
https://doi.org/10.55640/Keywords:
Nigella sativa, black cumin, thymoquinone, antioxidant, anti-inflammatory, medicinal plants, phytotherapy.Abstract
Nigella sativa (black cumin) has been utilized for centuries in traditional medicine systems across the Middle East, North Africa, and South Asia. Modern biomedical research increasingly validates its pharmacological potential, attributing diverse therapeutic effects primarily to its bioactive compound thymoquinone. Findings suggest that Nigella sativa demonstrates significant therapeutic promise, although further standardized clinical trials are required to confirm dosage safety and long-term efficacy. Evidence from both in vitro, in vivo, and clinical research suggests that Nigella sativa demonstrates significant therapeutic potential across multiple physiological systems. However, despite promising results, challenges remain regarding dosage standardization, extraction methods, and the need for large-scale randomized clinical trials. The findings highlight the potential of Nigella sativa as a valuable natural therapeutic agent and emphasize the need for further research to establish standardized clinical applications.Downloads
References
1.Ahmad A., et al. (2013). A review on therapeutic potential of Nigella sativa. Asian Pacific Journal of Tropical Biomedicine, 3(5), 337–352.
2.Woo C.C., et al. (2012). Thymoquinone: Potential cure for inflammatory disorders and cancer. Biochemical Pharmacology, 83(4), 443–451.
3.Randhawa M.A., & Alghamdi M.S. (2011). Anticancer activity of Nigella sativa. American Journal of Chinese Medicine, 39(6), 1075–1091.
4.Bamosa A.O., et al. (2010). Effect of Nigella sativa seeds on glycemic control in type 2 diabetes. Indian Journal of Physiology and Pharmacology, 54(4), 344–354.
5.Salem M.L. (2005). Immunomodulatory properties of Nigella sativa. International Immunopharmacology, 5(13–14), 1749–1770.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India